RxDoctor Payments Data

Jason Knighton, NP

Family · Pocatello, IDNPI 1285199869

Payments from drug & device makers

$518in general payments, 2019–2025

Across 23 payments — averaging $22.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$166
  • Mimedx Group, Inc.$162
  • Lilly USA, LLC$47
  • Ironshore Pharmaceuticals Inc.$19
  • Arbor Pharmaceuticals, Inc.$16
  • Novo Nordisk$16
  • plus $91 from 7 others

What the payments were for

  • Food & beverage$518100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$518 in reported general payments places this provider in the 55th percentile of 809 family providers in Idaho.

See all family providers in Idaho

Medicare billing

Part B allowed, 2024
$95,065
Medicare patients
128
Services billed
888

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban172$95,875
VraylarCariprazine Hcl39$47,880
BiktarvyBictegrav/Emtricit/Tenofov Ala11$45,312
Invega SustennaPaliperidone Palmitate11$39,514
XareltoRivaroxaban52$30,306
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$28,699
MyrbetriqMirabegron53$25,448
OzempicSemaglutide27$24,979
FarxigaDapagliflozin Propanediol40$22,737
NuedextaDextromethorphan Hbr/Quinidine11$17,541
Aripiprazole71$15,364
JanuviaSitagliptin Phosphate25$14,705
JardianceEmpagliflozin23$14,244
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog38$13,310
Fiasp FlextouchInsulin Aspart (Niacinamide)21$12,418

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$95,875172 claims
Johnson & JohnsonInvega Sustenna, Xarelto$16$69,82063 claims
AbbVieVraylar, Linzess$166$55,74453 claims
Novo NordiskOzempic$16$24,97927 claims
Boehringer IngelheimJardiance, Spiriva Respimat$12$22,89239 claims
Lilly USA, LLCTrulicity$47$11,14911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 809 family providers in Idaho.

Other family in Pocatello

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →